Sanofi press release (SNY): Q3 Non-GAAP EPS of â¬3.55 beats by â¬2.04. - Revenue of â¬14.44B (+16.2% Y/Y) beats by â¬1.12B. - Pharma launches sales increased by 31.4%, reaching â¬1.4 billion, driven by ALTUVIIIO, Ayvakit, and Rezurock. - Dupixent sales increased by 34.8% to...</p
Sanofi press release (SNY): Q3 Non-GAAP EPS of â¬3.55 beats by â¬2.04. – Revenue of â¬14.44B (+16.2% Y/Y) beats by â¬1.12B. – Pharma launches sales increased by 31.4%, reaching â¬1.4 billion, driven by ALTUVIIIO, Ayvakit, and Rezurock. – Dupixent sales increased by 34.8% to…
5.7 billion, above â¬5 billion per quarter
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
